Cr-labeled target cells from five different cell lines of AML origin were added for 4 h. Percent lysis was determined and plotted over four effector:target (E:T) ratios. Our results indicated that IL-12 was able to enhance lysis of all cell lines tested at у5 units/ml. When IL-2 was added to the culture at a low dose along with IL-12, there appeared to be a synergistic effect. Although anti-gamma interferon was able to inhibit the cytolytic potential of effectors activated by IL-12, the lysis could not be completely blocked. Thus, it appears that IL-12 has the ability to stimulate NK lysis indirectly through the induction of gamma interferon as well as an alternate mechanism not related to gamma interferon. Thus, IL-12 may have a beneficial role in the treatment of non-lymphoid leukemia.
Introduction
Patients with acute myeloid leukemia (AML) have a poor prognosis with standard chemotherapy. Although initial response rates now approach 85% in some trials, 1 most patients eventually relapse unless they undergo an HLA-matched, relateddonor bone marrow transplant. 2 Recent attention has been directed at innovative methods of therapy for AML patients in clinical remission who presumptively have sub-clinical minimal residual disease (MRD). One particularly interesting and promising approach has been the use of cytokines to induce or enhance the activity of natural killer cells resulting in lymphokine activated killer (LAK) cells. IL-2 has been studied extensively in vitro and in clinical trials and appears to have a wide range of efficacy in solid tumors and hematologic malignancies, particularly in the setting of MRD. [3] [4] [5] However, the high dose of human recombinant IL-2 necessary to generate sufficient LAK-mediated anti-tumor effects leads to significant side-effects, including high fevers, myalgias, arthralgias, capillary leak syndrome and ARDS. 6 New biologic agents with equivalent (or greater) immunomodulatory effects, but with less toxicity than IL-2, are currently being investigated. One such agent is IL-12, or natural killer cell stimulating factor (NKCSF). IL-12 activates cytotoxic lymphocytes and natural killer cells and also induces interferon gamma production. 7, 8 It has demonstrated activity against solid tumor cell lines and murine solid tumor xenograft models. [9] [10] [11] Recently, reports 13 have demonstrated in vitro activity against human AML cells by NK cells exposed to IL-12 and IL-2. Their experiments revealed that the combination of IL-12 and IL-2 resulted in a six-fold increase in lytic activity against AML blasts compared to a two-fold increase when the agents were used alone.
Because of these promising early data and the lack of basic information regarding the effect of IL-12 on LAK activity against AML, we have investigated the role of IL-12, with and without IL-2, in LAK-mediated anti-leukemic activity against five AML cell lines. Our results suggest that IL-12 has the potential for broad application as an anti-AML agent, particularly in light of its superior toxicity profile compared to IL-2.
Materials and methods

Reagents
IL-12 was supplied by the Genetics Institute (Cambridge, MA, USA) as part of an Extramural Research Agreement. The IL-12 had a specific activity of 5.26 × 10 6 units/mg of protein. IL-2 was supplied by Hoffman-LaRoche (Philadelphia, PA, USA). The mouse monoclonal antibody to human gamma interferon (AFI) was purchased from Biosource (Camarillo, CA, USA), and resuspended in media to appropriate concentrations. The control or irrelevant antibody was a murine monoclonal IgG to human IgG (Immunotech, Westbrook, ME, USA).
Cell culture
The AML cell lines were obtained from the ATCC (Rockville, MD, USA). Mycoplasma free cell lines were cultured in 90% RPMI1640 + 10% fetal calf serum (FCS). The target cells utilized were the cell lines of AML origin including K562 (chronic myelogenous leukemia), HEL (a human erythroleukemia cell line), HL-60 (a cell line derived from human acute promyelocytic leukemia, U937 (a cell line derived from a patient with diffuse histiocytic lymphoma with monocytic attributes), and KG1-a (a chemoresistant undifferentiated promyeloblastic leukemia cell line). Cells were maintained in logarithmic growth with cell densities ranging from 0.2 to 0.75 million cells/ml.
Killer cell activity
Normal peripheral blood mononuclear cells (PBMC) were collected from volunteers and utilized as effector cells in a standard chromium release assay. Briefly, PBMC were isolated over a Ficoll-Hypaque gradient, washed, resuspended in RPMI1640 + 10% FCS media with various concentrations of IL-12 NK assay of U937, KG-1a, K562, HEL and HL-60: y axis is the percent specific lysis of the cell line by normal effectors incubated with media (control), 1000 IU/ml of IL-2 (IL-2), or varying concentrations of IL-12. X axis is the E:T ratio of 6.25:, 12.5:1, 25:1 and 50:1. Points represent the mean and bars are calculated standard error throughout the figures. U937: The difference between IL-12 and media is significant for all concentrations except 0.5 IU/ml. n = 11, P = 4.87 × 10 −19 by ANOVA, P Ͻ 0.05 by Bonferroni's method comparing IL-12 to media except at 0.5 IU/ml. KG1-a: The difference between IL-12 and media is significant for all concentrations except 0.5 IU/ml. n = 10, P = 6.82 × 10 −18 , P Ͻ 0.05 by Bonferroni's method except at 0.5 IU/ml. K562: The difference between IL-12 and media is significant for all concentrations except 0.05 IU/ml. n = 7, P = 1.67 × 10 −8 , P Ͻ 0.05 by Bonferroni's method comparing IL-12 to media except at 0.5 IU/ml. HEL: The difference between IL-12 and media is significant for all concentrations except 5 IU/ml by ANOVA. n = 6, P = 6.92 × 10 . P Ͻ 0.05 by Bonferroni's method comparing IL-12 to media except at 5 and 0.5 IU/ml. HL-60: The difference between IL-12 and media is significant for all concentrations except 0.5 IU/ml. n = 6, P = 4.66 × 10 where c.p.m. is counts per minute, Exp. is experimental sample counts, SR is spontaneous release, and MR is maximum release. Spontaneous release was determined by adding media to target cells, while maximum release was determined by adding 0.5% Triton-X100 to the target cells. All assays were performed in triplicate. The number of separate experiments (n) is listed in the figure legends. The control in all assays was media without any interleukin. IL-2 was 1000 IU/ml final concentration unless otherwise stated. The IL-12 is listed as IU/ml final concentration. Fifty IU/ml IL-12 is approximately 9.5 ng/ml of protein.
Statistics
Each cell line was evaluated first by the one way repeated measures analysis of variance. The alpha was set at 0.05 and the power equal to or greater than 0.80. If the difference in the mean values among the groups was greater than expected, a multiple comparison procedure was performed. The two procedures utilized were the all pairwise multiple comparison procedure (Student-Newman-Keuls method), and the comparison of all groups vs a control group using the Bonferroni's method. A P value of less than 0.05 was considered significant.
Results
IL-12 enhanced lysis of AML cell lines
In an effort to determine the responsiveness of effector cells to IL-12, normal effector cells were incubated with media, IL-2, or varying concentrations of IL-12, and the non-MHC restricted lytic activity was measured by chromium release of the lysed AML cell line targets. There was consistent enhanced lysis of all targets following incubation with IL-12 compared to controls (effectors in media alone). The percentage of targets lysed was directly proportional to the concentration of IL-12 added and to the E:T ratio (Figure 1 ). Significant lysis was seen at E:T ratios of 50:1 and 25:1, with concentrations of IL-12 as low as 5 IU/ml in all cell lines (Figure 1 ). At E:T ratios of 12.5:1, higher concentrations of IL-12 were required to induce observable differences in lysis compared to media alone.
Combination low-dose IL-12 and IL-2
Sub-optimal concentrations of IL-2 or IL-12 alone do not enhance LAK activity significantly. Uharek et al 13 reported additive effects were seen only with higher concentrations of both IL-2 and IL-12. The purpose of this experiment was to determine if sub-optimal concentrations would increase LAK activity significantly. These experiments were performed in two of the five cell lines due to the labor intensiveness of the studies.Because the results between KG1-a and U937 were similar, only the results from the cell line KG1-a are illustrated. KG1-a (Figure 2 ), the combination of IL-12 at 0.5, 1.0 or 5.0 IU/ml with a sub-optimal concentration of IL-2 (2.5 IU/ml) led to significant enhancement of lysis compared to either agent alone (P Ͻ 0.05) at all E:T ratios. This increase is greater than the sum of the two individual agents alone. Thus, the combination of agents appeared to be additive at an E:T ratio of 50:1 and synergistic at the other E:T ratios. We were curious if the combination of the maximum concentration of IL-2 and IL-12 would increase the percent specific lysis. In preliminary experiments, we were never able to exceed the amount of lysis produced by either agent alone at the highest concentrations of cytokines. Thus, no further experiments were conducted with those concentrations.
Anti-gamma interferon
Previous investigations into the mechanism of action of IL-12 have shown that IL-12 increases the amount of gamma interferon produced. If gamma interferon was blocked by the addition of a specific antibody, then any interferon effect would be negated. Because there was little difference between the activity of IL-12 at the three highest concentrations of IL-12 in U937, we chose 50 IU/ml and the cell line U937 to illustrate these effects. When IL-2 and anti-gamma interferon were added together to the effector cell incubation for 18 h, no inhibition of LAK activity against U937 was demonstrated. This was in contrast to the nearly linear inhibition of IL-12 induced LAK activity (Figure 3 ). Lower concentrations of IL-2 and IL-12 were added to effector cells alone and in combination with varying concentrations of the monoclonal antibody to gamma interferon (Figure 4) . Similar inhibition curves were obtained when these lesser concentrations of cytokines were used individually as demonstrated in Figure 3 . However, when both cytokines were added simultaneously to the effec-
Figure 3
Inhibition of LAK activity against U937 by anti-gamma interferon. Percent specific lysis of the cell line U937 by effectors activated with IL-2 (1000 IU/ml) or IL-12 (50 IU/ml) with varying concentrations of anti-gamma interferon. Media is no cytokine or antibody, and 0 anti-gamma interferon is no antibody in the presence of IL-2 or IL-12. Cells were incubated overnight with one of the cytokines and antibody prior to the addition of the labeled U937 target cells. IL-12 P Ͻ 0.05 at all concentrations of anti-gamma interferon. There is no statistical difference between 100 and 1000 ng/ml of anti-gamma interferon. (E:T ratio is 50:1, n = 3, one way ANOVA, error bars are calculated standard error of the mean).
tor cells, the inhibition of lysis by the antibody was similar to that with IL-12 alone (Figure 4) . In separate experiments, the dose response curve of anti-gamma interferon in the presence of IL-12 against the cell lines U937, KG1-a and K562 compared to the irrelevant antibody control as shown ( Figure 5 ; not all data are plotted for the lower doses of the control antibody). Experiments were completed at all four E:T ratios, but only the data at the 50:1 ratio are shown. There was no inhibition of LAK activity by the control antibody. Anti-gamma interferon was able to decrease the amount of cell lysis proportional to the dose of the antibody. There were no cytotoxic effects on any of the target cells when incubated in either cytokine for 4 h and then counted for viability.
Discussion
Our primary objective was to determine the effect of IL-12 on the cell-mediated cytotoxicity of normal human PBLs against myeloid leukemia cell lines. We also wanted to determine the additive effects of sub-optimal as well as high concentrations of IL-12 and IL-2 on LAK activity. Finally, we wanted to assess the role of gamma interferon in IL-12-induced LAK activity against AML targets. We have demonstrated that IL-12 augments cell-mediated cytotoxicity of various myeloid leukemia cell lines in a manner which is directly proportional to both the concentrations of IL-12 and the E:T ratio, although some lines seemed more sensitive to IL-12-induced LAK activity. Combined exposure to sub-optimal concentrations of IL-12 and IL-2 led to enhanced lysis compared to either agent alone,
Figure 4
Inhibition of specific lysis of U937 by anti-gamma interferon antibody. Percent specific lysis of the cell line U937 by normal effectors incubated overnight with media, IL-2 (2.5 IU/ml), IL-12 (1 IU/ml), or the combination of both cytokines in varying concentrations of the mouse monoclonal antibody to human gamma interferon. (E:T ratio of 50:1; n = 4, error bars are calculated standard error of the mean.) while the use of combined high concentrations of both agents did not increase the lytic activity. We were also able to demonstrate that the IL-12 effect was only partially blocked by anti-gamma interferon.
The targets in these experiments represented cell lines derived from several myeloid leukemia phenotypes including promyelocytic, monocytic, erythroid and chronic myelogenous. These cell lines were chosen due to their cell of origin, the reproducibility of the measured effects which can be difficult to obtain when using stored patient samples, and the ability to complete multiple studies using various cytokine concentrations and antibodies which would be difficult to repeat using readily available patient samples. The lack of NK lysis susceptibility is easily seen by the low level of lysis when the effectors were not stimulated with any cytokine but incubated in media alone. The maximum LAK activity is also easily seen using the curve generated when the effectors were incubated in 1000 IU/ml of IL-2. K562 is often used as a standard target in NK functional assays because of its sensitivity to NK lysis. Even though KG-1a, HEL, HL-60 may not be sensitive to NK lysis they, as well as K562 and U937 are readily lysed by LAK cells.
IL-12 is a cytokine previously known as natural killer cell stimulating factor. This particular cytokine has numerous effects on the immune system including stimulation of NK activity, and induction of the production of interferon gamma. 8 The ability of IL-12 to enhance the effect of IL-2 on NK activity, as shown in our combination experiments with IL-2 and IL-12, may be related to the synergistic effect of these two cytokines on the production of gamma interferon. IL-12 inhibition with anti-gamma interferon. Effector cells were incubated with IL-12 (50 IU/ml) and increasing concentrations of antibody to interferon gamma (listed in the legend) or the control antibody overnight. The designated target cells were added at all four E:T ratios and the specific lysis determined. Only the data from the 50 E:T ratio and the highest concentration of control antibody are shown along with the titrated anti-gamma interferon. (n = 3 per cell line tested, error bars are calculated standard error of the mean.) tor cells and cytokines. Antibody to gamma interferon did not alter the LAK lysis induced by IL-2 when used alone. However, when IL-12 was the stimulating cytokine, there was a near linear inhibition of NK lysis proportional to the concentration of anti-gamma interferon. The inhibition appeared to maximize at 100 ng/ml of anti-gamma interferon, but not completely eradicate the specific cell-mediated lysis. Finally, when sub-optimal concentrations of IL-2 and IL-12 were used together as in the previous experiments, the effect of antigamma interferon was similar to the previous experiments. However, IL-2 was not able to protect the effector cells from the inhibition related to the antibody to gamma interferon in the presence of IL-12. These data suggest that when effector cells are exposed to IL-2 and IL-12 simultaneously the ability of cells to respond to IL-2 may be altered. The mechanism for this alteration requires further investigation. The use of the control antibody compared to increasing concentrations of anti-gamma interferon demonstrated the specificity of the results regarding the antibody to gamma interferon.
The receptors for IL-2 binding and IL-12 binding appear to be different sites on the cell surface. 15 The effects of IL-2 binding have been well described and the reader is referred to a review article on this subject. 16 IL-12 binding has been shown to stimulate different intracellular messages. 17 One well-measured outcome of IL-12 stimulation is the increase in cellular production of gamma interferon. It has been shown that some of the cellular events due to IL-12 are a result of the increase in gamma interferon production. This may also be the mechanism for the toxicity of IL-12 recently published. 18 A recent study has also shown that after stimulation with IL-2 and IL-12 together, the gamma interferon production peaks and then declines dramatically. The investigators showed the mechanism for this decline in production was due to an increase in apoptosis of the NK cells. This was a time-dependent event requiring greater than 48 h of incubation with the cytokine. 19 Our effector cells were incubated for less than half that time. Although our data are consistent with previous investigations regarding the ability to enhance LAK activity, these data clearly demonstrate the ability of IL-12 to enhance LAK activity against AML cell lines. With current clinical studies investigating the role of IL-2 therapy in AML, the option of another biologic with a different toxicity profile may be important to future clinical trials. This study also brings up further questions regarding other mechanisms of action of IL-12 to induce LAK activity. Although, determining such alternate pathways was not the objective of this study, speculation can be made. We have clearly shown that antibody to gamma interferon does not inhibit LAK activity when IL-2 is the activ-ating cytokine, and that LAK activity is inhibited but not completely blocked when IL-12 is the activating cytokine. These results suggest that another mechanism of action other than gamma interferon NK activation or target lysis is the mechanism of action. Also, one would have predicted that the combination of IL-2 and IL-12 would not be blocked by antigamma interferon due to the presence of IL-2. Yet, when these agents were used simultaneously, the ability of anti-gamma interferon to block LAK activity was not altered. This event suggested that in the presence of IL-12, LAK activity induced by the cytokines is induced in such a way that the role of IL-2 activation is altered and cannot overcome the anti-gamma interferon blockade.
IL-12 has previously demonstrated anti-tumor activity in other models. In mice with transplanted cancers, including melanoma and sarcoma, IL-12 induced regression which appeared to be independent of NK cells but may have been dependent on T cells. 9 Locally placed fibroblasts engineered to produce IL-12 induce complete tumor regression in a mouse sarcoma model. 10 These types of data may suggest that prolonged exposure to small concentrations of IL-12 may not only be feasible, but clinically relevant. Our data regarding augmentation of lysis at low concentrations would agree with this principal. The mechanism by which IL-12 is able to alter tumor growth and metastatic potential is still not clear. Possible explanation includes NK cell lysis, T cell cytotoxicity, direct effect of gamma interferon, and possibly as an anti-angiogenic factor. Cesano et al 12 demonstrated a role of IL-12 in AML also using a mouse model. These investigators injected a SCID mouse model with U937 cells while also giving the mice a T cell clone able to lyse U937 cells in a non-MHC restricted fashion, and simultaneously injected systemic IL-12. The mice could be 'cured' of the leukemia by the administration of repeated low doses of IL-12 and the T cell clone. The most interesting result in the study was that cure could also be achieved when the T cells were irradiated, and the mice continued to receive IL-12. IL-12 has also induced NK activity against neuroblastoma cells from pediatric patients implying NK augmentation can occur even in the presence of an underlying illness. 11 The role of IL-12 in leukemia has just recently begun to be evaluated. 13 Uharek et al's recent report supports our data that IL-12 is able to enhance cytolysis of leukemia cells. The differences though that we found included a more linear dose-response to IL-12, and the ability to dramatically increase lysis of the target cells with the combination of lower doses of IL-2 and IL-12. Recent human clinical trials have stimulated interest in the use of biologic response modifiers, especially IL-2, as agents able to eradicate minimal residual disease (MRD). 6, 20 Our data demonstrate that IL-12 can enhance the cell-mediated lysis of AML cell lines in vitro. This enhancement is evident at lower doses and may be additive when given in combination with IL-2. Thus, the next step is to determine the ability of IL-12 to enhance lysis of myeloblasts from patients with AML.
